Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 159,300 shares, a decline of 25.1% from the October 15th total of 212,600 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average trading volume of 642,000 shares, the days-to-cover ratio is presently 0.2 days.

Achilles Therapeutics Stock Up 1.0 %

Shares of Achilles Therapeutics stock opened at $1.02 on Thursday. Achilles Therapeutics has a 1 year low of $0.63 and a 1 year high of $1.76. The business has a fifty day simple moving average of $0.94 and a two-hundred day simple moving average of $0.87.

Achilles Therapeutics (NASDAQ:ACHL) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Sell-side analysts predict that Achilles Therapeutics will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd increased its position in Achilles Therapeutics by 239.4% during the second quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock worth $42,000 after acquiring an additional 36,441 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Achilles Therapeutics in the first quarter valued at approximately $350,000. StemPoint Capital LP acquired a new position in Achilles Therapeutics in the 1st quarter valued at $1,732,000. Ikarian Capital LLC bought a new stake in shares of Achilles Therapeutics during the 1st quarter valued at $1,804,000. Finally, BML Capital Management LLC grew its holdings in shares of Achilles Therapeutics by 555.8% during the 3rd quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock worth $4,182,000 after purchasing an additional 3,474,828 shares in the last quarter. Institutional investors own 56.38% of the company’s stock.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.